The observed reduction in serum IL-17a levels in this cohort is consistent with the findings of Jabeen and colleagues [7], Karpisheh and colleagues [8], and Tzang and colleagues [9], that chemotherapy and anti-angiogenic therapies modulate immune responses during BC treatment, thereby underscoring the potential immunosuppressive effect of chemotherapy. This evidence concerns the gene IL17A and breast cancer.